Laryngoscope:过敏性鼻炎中鼻流峰值可逆性与粘液纤毛清除关系研究

2019-08-17 AlexYang MedSci原创

鼻减充血后利用鼻腔测压测量的鼻气流可逆性与过敏性炎症的严重度相关。峰值鼻气流是一种较为简单的评估鼻开放性的方法。最近,有研究人员评估了鼻减充血后鼻呼气和吸气流量峰值(PNEFs和PNIFs)变化与鼻粘膜纤毛清除时间(NMCCTs)的关系。研究是一个单中心的、前瞻性代表性研究,共包括了101名过敏性鼻炎患者。研究人员评估了鼻症状和NMMCCTs,并在减充血后进行了PNEF和PNIF测量。研究发现,在

鼻减充血后利用鼻腔测压测量的鼻气流可逆性与过敏性炎症的严重度相关。峰值鼻气流是一种较为简单的评估鼻开放性的方法。最近,有研究人员评估了鼻减充血后鼻呼气和吸气流量峰值(PNEFs和PNIFs)变化与鼻粘膜纤毛清除时间(NMCCTs)的关系。

研究是一个单中心的、前瞻性代表性研究,共包括了101名过敏性鼻炎患者。研究人员评估了鼻症状和NMMCCTs,并在减充血后进行了PNEF和PNIF测量。研究发现,在鼻减充血后,PNEF表现除了鼻PNIF更多的峰值气流改善。与PNIF相比,PNEF的变化与NMCCTs具有更好的相关性(分别为ρ=-0.49, P<0.001和ρ=-0.34, P<0.001)。PNEF和PNIF的最小临床重要差异(MCID)值分别为27.93和19.74。在减充血红峰值鼻流具有MCID和不具有MCID的患者的NMCCTs比较中,PNEF具有比PNIF更好的区分能力(分别为P=0.003和P=0.026)。

最后,研究人员指出,鼻血流峰值测量的可逆性的限制能够间接指出NMCCTs所表明的粘膜炎症的影响。PNEF要比PNIF在评估减充血后鼻流峰值变化中更加敏感。

原始出处:

Kirtsreesakul V, Leelapong J, Ruttanaphol S et al. Correlation Between Peak Nasal Flow Reversibility and Mucociliary Clearance in Allergic Rhinitis. Laryngoscope. 06 Aug 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728103, encodeId=7a6c1e28103a3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 26 14:08:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047148, encodeId=ce24204e1482d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jul 11 17:08:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580251, encodeId=8e9c1580251e7, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Mon Aug 19 02:08:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371417, encodeId=11713e141792, content=值得关注。下一步研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ff45165790, createdName=146c765cm75暂无昵称, createdTime=Sat Aug 17 23:22:29 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-11-26 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728103, encodeId=7a6c1e28103a3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 26 14:08:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047148, encodeId=ce24204e1482d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jul 11 17:08:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580251, encodeId=8e9c1580251e7, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Mon Aug 19 02:08:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371417, encodeId=11713e141792, content=值得关注。下一步研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ff45165790, createdName=146c765cm75暂无昵称, createdTime=Sat Aug 17 23:22:29 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728103, encodeId=7a6c1e28103a3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 26 14:08:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047148, encodeId=ce24204e1482d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jul 11 17:08:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580251, encodeId=8e9c1580251e7, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Mon Aug 19 02:08:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371417, encodeId=11713e141792, content=值得关注。下一步研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ff45165790, createdName=146c765cm75暂无昵称, createdTime=Sat Aug 17 23:22:29 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728103, encodeId=7a6c1e28103a3, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Tue Nov 26 14:08:00 CST 2019, time=2019-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047148, encodeId=ce24204e1482d, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Jul 11 17:08:00 CST 2020, time=2020-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580251, encodeId=8e9c1580251e7, content=<a href='/topic/show?id=76743853197' target=_blank style='color:#2F92EE;'>#可逆性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38531, encryptionId=76743853197, topicName=可逆性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=023016601943, createdName=小华子, createdTime=Mon Aug 19 02:08:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371417, encodeId=11713e141792, content=值得关注。下一步研究方向。, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ff45165790, createdName=146c765cm75暂无昵称, createdTime=Sat Aug 17 23:22:29 CST 2019, time=2019-08-17, status=1, ipAttribution=)]
    2019-08-17 146c765cm75暂无昵称

    值得关注。下一步研究方向。

    0

相关资讯

Int J Pediatr Otorhinolaryngol:过敏性鼻炎儿童患者呼出一氧化氮水平比较研究

最近,有研究人员确定了是否测量呼出一氧化氮(eNO)水平能够帮助区分过敏性鼻炎(AR)儿童和健康对照,并探究了是否AR与疾病严重度相关。研究包括了5-15岁的儿童,并分成了过敏性鼻炎组(n=40)和健康对照组(n=40)。研究进行的时间为2015年8月到2016年。研究人员根据ARIA分类将eNO水平与患者的临床疾病严重度进行了比较。研究发现,AR儿童中eNO水平(12.64±14.67ppb)要

Immunotherapy:MiR-146a类似物能够减轻过敏性鼻炎

最近,有研究人员调查了microRNA(miR)-146a在过敏性鼻炎(AR)中的治疗潜力情况。研究人员将雌性BALB/c小鼠随机分配到AR和miR-146a组。在第21-28天每天进行卵清蛋白(OVA)挑战之前,研究人员进行了鼻孔miR-146a给药。研究发现,miR-146a的表达水平在AR鼻粘膜中显著减少。miR-146a类似物能够显著的减轻打喷嚏和挠鼻事件,并减少卵清蛋白特异性lgE水平,

Int Arch Allergy Immunol:RORA过表达能够减轻鼻粘膜损伤和增强红细胞免疫粘附功能

最近,有研究人员调查了是否RORA(维甲酸受体相关的孤儿受体α)能够减轻过敏性鼻炎(AR)的恶化。为了阐释RORA和RORTA与Wnt/β-catenin信号途径之间的调控机制可能产生的影响,研究人员建立了AR小鼠模型并利用RORA相关载体或者Wnt/β-catenin信号途径抑制剂WIF-1进行了相关处理。之后,研究人员测量了各种指标。研究发现,OVA诱导的AR小鼠模型表现出了明显的鼻粘膜损伤和

鼻炎太难受!盐水洗鼻用上就能缓解 但这2点没做好效果大打折扣

在现在的生活当中鼻炎出现的次数是非常多的,而且有非常多的人都患有鼻炎,鼻腔很容易成为人们的一个卫生死角,由于方法不当而不能全面彻底清除鼻腔中的有害物质,不少病毒、灰尘很可能在鼻腔中躲藏,从而引发感冒、充血、感染。据调查了解10个人里面大概有7个人都会患有鼻炎。盐水洗鼻是近几年来比较流行的治疗鼻炎新方法,效果不错、操作简单的盐水洗鼻成了很多鼻炎患者的首选,不过在使用这个方法的时候也有许多的误区。

Complement Ther Med:小青龙汤治疗常年性变应性鼻炎的效果和安全性多中心研究

小青龙汤(SCRT)是一种混合的中草药,常用于治疗过敏性鼻炎、支气管炎、过敏性哮喘和普通感冒。最近,有研究人员评估了SCRT在治疗过敏性鼻炎中的疗效和安全性情况。研究人员进行的是一个双盲、随机、安慰剂对照、平衡组和多中心的研究。主要结果为总鼻症状评分的变化,次级结果包括了鼻炎生活治疗调查问卷得分变化,总血清免疫球蛋白E(lgE)变化和细胞因子水平以及鼻内镜指数变化。研究发现,在PAR患者中4周的S

Allergy Asthma Immunol Res:吸尘床垫对过敏性鼻炎儿童症状的影响

最近,有研究人员在HDM敏感的儿童中评估了日常使用的吸尘床垫对屋尘螨(HDM)过敏原浓度和过敏性鼻炎(AR)症状的影响。研究包括了40名6岁到12岁的儿童,他们具有轻度持续性AR,并且只对HDM敏感。研究人员将其分成了2个小组,实验组中,儿童看护人将儿童居住的房间清理并每天都对床垫吸尘处理,共持续2周;而对照组儿童看护人只清理了房间,不对床垫进行吸尘处理。研究发现,人口统计资料在2个小组中没有显出